Changes

HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma (view source)

Revision as of 17:09, 6 September 2024

1,679 bytes added , 6 September

no edit summary

Line 1: Line 1:

{{DISPLAYTITLE:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma}}

−

[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]

+

[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

−

<blockquote class='blockedit'>{{Box-round|title=~~HAEM5 Conversion Notes~~|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Primary Cutaneous Anaplastic Large Cell Lymphoma]].

+

<blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Primary Cutaneous Anaplastic Large Cell Lymphoma]].

}}</blockquote>

−

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author_Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [mailto:CCGA@cancergenomics.org Technical Support])

+

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author_Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [mailto:CCGA@cancergenomics.org Technical Support])

==Primary Author(s)*==

Line 50: Line 50:

==Clinical Features==

−

Put your text here and fill in the table (''Instruction: Can include references in the table'')

+

Put your text here and fill in the table (''Instruction: Can include references in the table. Do not delete table.'')

{| class="wikitable"

|'''Signs and Symptoms'''

−

|EXAMPLE Asymptomatic (incidental finding on complete blood counts)

+

|EXAMPLE: Asymptomatic (incidental finding on complete blood counts)

−

EXAMPLE B-symptoms (weight loss, fever, night sweats)

+

EXAMPLE: B-symptoms (weight loss, fever, night sweats)

−

EXAMPLE Fatigue

+

EXAMPLE: Fatigue

−

EXAMPLE Lymphadenopathy (uncommon)

+

EXAMPLE: Lymphadenopathy (uncommon)

|-

|'''Laboratory Findings'''

−

|EXAMPLE Cytopenias

+

|EXAMPLE: Cytopenias

−

EXAMPLE Lymphocytosis (low level)

+

EXAMPLE: Lymphocytosis (low level)

|}

Line 139: Line 139:

!Notes

|-

−

|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)

+

|EXAMPLE: t(9;22)(q34;q11.2)||EXAMPLE: 3'ABL1 / 5'BCR||EXAMPLE: der(22)||EXAMPLE: 20% (COSMIC)

−

EXAMPLE 30% (add reference)

+

EXAMPLE: 30% (add reference)

|Yes

|No

|Yes

−

|EXAMPLE

+

|EXAMPLE:

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).

Line 174: Line 174:

==Individual Region Genomic Gain / Loss / LOH==

−

Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')

+

Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'')

{| class="wikitable sortable"

Line 184: Line 184:

!Notes

|-

−

|EXAMPLE

+

|EXAMPLE:

7

−

|EXAMPLE Loss

+

|EXAMPLE: Loss

−

|EXAMPLE

+

|EXAMPLE:

chr7:1- 159,335,973 [hg38]

−

|EXAMPLE

+

|EXAMPLE:

chr7

Line 197: Line 197:

|Yes

|No

−

|EXAMPLE

+

|EXAMPLE:

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

|-

−

|EXAMPLE

+

|EXAMPLE:

8

−

|EXAMPLE Gain

+

|EXAMPLE: Gain

−

|EXAMPLE

+

|EXAMPLE:

chr8:1-145,138,636 [hg38]

−

|EXAMPLE

+

|EXAMPLE:

chr8

Line 214: Line 214:

|No

−

|EXAMPLE

+

|EXAMPLE:

Common recurrent secondary finding for t(8;21) (add reference).

Line 246: Line 246:

==Characteristic Chromosomal Patterns==

−

Put your text here (''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')

+

Put your text here (''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')

{| class="wikitable sortable"

Line 256: Line 256:

!Notes

|-

−

|EXAMPLE

+

|EXAMPLE:

Co-deletion of 1p and 18q

Line 262: Line 262:

|No

−

|EXAMPLE:

+

|EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

Line 274: Line 274:

==Gene Mutations (SNV / INDEL)==

−

Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'')

+

Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.'')

{| class="wikitable sortable"

Line 284: Line 284:

!Notes

|-

−

|EXAMPLE: TP53; Variable LOF mutations

+

|EXAMPLE: TP53; Variable LOF mutations

−

EXAMPLE:

+

EXAMPLE:

EGFR; Exon 20 mutations

−

EXAMPLE: BRAF; Activating mutations

+

EXAMPLE: BRAF; Activating mutations

−

|EXAMPLE: TSG

+

|EXAMPLE: TSG

−

|EXAMPLE: 20% (COSMIC)

+

|EXAMPLE: 20% (COSMIC)

−

EXAMPLE: 30% (add Reference)

+

EXAMPLE: 30% (add Reference)

−

|EXAMPLE: IDH1 R123H

+

|EXAMPLE: IDH1 R123H

−

|EXAMPLE: EGFR amplification

+

|EXAMPLE: EGFR amplification

|

−

|EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).

+

|EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).

|}

Line 316: Line 316:

==Genes and Main Pathways Involved==

−

Put your text here and fill in the table (''Instructions: Can include references in the table.'')

+

Put your text here and fill in the table (''Instructions: Can include references in the table. Do not delete table.'')

{| class="wikitable sortable"

|-

!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome

|-

−

|EXAMPLE: BRAF and MAP2K1; Activating mutations

+

|EXAMPLE: BRAF and MAP2K1; Activating mutations

−

|EXAMPLE: MAPK signaling

+

|EXAMPLE: MAPK signaling

−

|EXAMPLE: Increased cell growth and proliferation

+

|EXAMPLE: Increased cell growth and proliferation

|-

−

|EXAMPLE: CDKN2A; Inactivating mutations

+

|EXAMPLE: CDKN2A; Inactivating mutations

−

|EXAMPLE: Cell cycle regulation

+

|EXAMPLE: Cell cycle regulation

−

|EXAMPLE: Unregulated cell division

+

|EXAMPLE: Unregulated cell division

|-

−

|EXAMPLE: KMT2C and ARID1A; Inactivating mutations

+

|EXAMPLE: KMT2C and ARID1A; Inactivating mutations

−

|EXAMPLE: Histone modification, chromatin remodeling

+

|EXAMPLE: Histone modification, chromatin remodeling

−

|EXAMPLE: Abnormal gene expression program

+

|EXAMPLE: Abnormal gene expression program

|}

Bailey.Glen

Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors

2,501

edits